Pfizer and BioNTech announced that Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, will manufacture COVID-19 vaccines for distribution within Latin America.
Eurofarma will manufacture COVID-19 vaccines as part of Pfizer and BioNTech’s global COVID-19 vaccine supply chain and manufacturing network, which now spans four continents and includes over 20 manufacturing facilities.
Chairman and Chief Executive Officer of Pfizer Albert Bourla said that their collaboration with Eurofarma “expands our global supply chain network to another region.”
“Our new collaboration with Eurofarma expands our global supply chain network to another region – helping us continue to provide fair and equitable access to our COVID-19 vaccine. We will continue to explore and pursue opportunities such as this to help ensure that vaccines are available to all who are in need,” Bourla said.
Bourla emphasized that everyone deserves to be inoculated with vaccines against COVID-19.
“Everyone – regardless of financial condition, race, religion or geography – deserves access to lifesaving COVID-19 vaccines,” Bourla said.
The Pfizer and BioNTech vaccine deal with Biovac of South Africa last month was structured similarly. It calls for the annual production of over 100 million doses for distribution across the continent. A fill-finish factory in Cape Town will receive drug substance from European facilities.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.